Alzheimer’s disease drugs that target amyloid-β, one of the problematic proteins associated with the disease, may have “no ...

Study under fire for mixing data on failed and new anti-amyloid therapies to draw conclusi ...

The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein ...

The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer's disease, despite the fact that a key FDA panel late last year said that questions remain about its ...

With incomplete data to guide aducanumab (Aduhelm) prescribing, neurologists face ethical challenges and will be guided best by established principles to counsel people with Alzheimer's disease and ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — More patients with early symptomatic Alzheimer’s disease reached amyloid clearance and plaque ...

As the controversial Alzheimer's disease (AD) drug aducanumab (Aduhelm) begins its integration into clinical practice, some physicians are concerned the drug's prescribing label does not include ...

Aducanumab (Aduhelm), the only monoclonal antibody approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer's disease (AD), removes amyloid from the brain and reduces ...

Biogen’s aducanumab, already hamstrung in the U.S. by a stifling coverage decision, won’t be hitting the European market anytime soon. Biogen has scrapped its filing for the Alzheimer’s disease drug ...